Abstract Library

#4583 Improved assessment of gene rearrangements by targeting non-coding DNA regions in patients diagnosed with pancreatic neuroendocrine neoplasms

Introduction: Whole-genome sequencing projects documented the heterogeneity of pancreatic neuroendocrine neoplasms (PanNEN), while showing that few core pathways are consistently affected in their tumorigenesis. Comprehensive genomic profiling (CGP) of real-world cases is expected to recapitulate such heterogeneity for patient stratification and to inform precision therapy. While coding DNA is the focus of current CGP panels, the potential of targeting non-coding DNA (ncDNA) to improve structural variants detection has not been widely explored in this context.

Conference:

Presenting Author: Agnoletto C

Authors: Agnoletto C, Trevisani E, Borghesani M, Landoni L, Luchini C,

Keywords: neuroendocrine, non-coding DNAs, structural variants, clinical relevance, CGP panel,

#4158 Transcriptomic analysis of PanNET tumor progression from microtumor to metastasis in MEN1 patients

Introduction: Pancreatic Neuroendocrine Neoplasms (PanNENs) are a major component the Multiple Endocrine Neoplasia 1 Syndrome (MEN1). Although multiple pancreatic neuroendocrine microtumors (microadenomatosis) are a histomorphological hallmark of MEN1, their molecular status compared to PanNET as well as their metastasis remains unclear.

Conference:

Presenting Author:

Authors: Chouchane A, Kirchner P, Sylvain Maire R, Schiavo Lena M, Falconi M,

Keywords: Microtumor, MEN1, PanNETs, RNAseq, Transcriptomics, Progression,

#3999 Exploring the biological and clinical heterogeneity of grade 2 pancreatic neuroendocrine tumors: Insights into diagnosis, prognosis, and therapeutic targets

Introduction: Pancreatic neuroendocrine neoplasms (PanNENs) show heterogeneous behavior, mainly related to their grade (G), nevertheless small well-differentiated G1 and G2 lesions are usually approached the same conservative way.

Conference:

Presenting Author:

Authors: Gallo C, Lorenzo Andrea C, Pietro I, Sara M,

Keywords: pancreas, neuroendocrine, survival, grading,

#3997 FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression

Introduction: More than 60% of pancreatic neuroendocrine neoplasms (PanNENs) represent metastases when diagnosed. Metabolic alterations have been recognized as one of the hallmarks of tumor metastasis. However, little is known about the molecular mechanism of metabolic changes regulating PanNEN progression.

Conference:

Presenting Author:

Authors: Hu C,

Keywords: metabolic alteration, tumor progression, pancreatic neuroendocrine neoplasm, FOXA2, INHBA, epithelial-mesenchymal transition,

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,